Assessment of subclinical atherosclerosis in psoriatic arthritis patients without clinically overt cardiovascular disease or traditional atherosclerosis risk factors
| Autor: | Omer Karadag, Kudret Aytemir, Sedat Kiraz, Levent Kilic, Şule Apraş Bilgen, Abdulsamet Erden, Ihsan Ertenli, Ali Akdogan, Uğur Canpolat, Umut Kalyoncu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male lcsh:Internal medicine lcsh:Diseases of the circulatory (Cardiovascular) system medicine.medical_specialty Turkey lcsh:Medicine Arthritis Coronary Artery Disease Carotid Intima-Media Thickness Severity of Illness Index Gastroenterology 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Risk Factors Internal medicine Psoriasis Prevalence Humans Medicine 030212 general & internal medicine lcsh:RC31-1245 030203 arthritis & rheumatology medicine.diagnostic_test business.industry Arthritis Psoriatic Cholesterol HDL lcsh:R Case-control study Cholesterol LDL Middle Aged medicine.disease arthritis Intima-media thickness lcsh:RC666-701 Case-Control Studies Rheumatoid arthritis Erythrocyte sedimentation rate Female Cardiology and Cardiovascular Medicine business Body mass index atherosclerosis endothelial dysfunction |
| Zdroj: | Türk Kardiyoloji Derneği Arşivi, Vol 46, Iss 5, Pp 358-365 (2018) |
| ISSN: | 1016-5169 |
| Popis: | Objective: Cardiovascular disease (CVD) is more prevalent in almost all patients with chronic inflammatory musculoskeletal diseases than in their healthy counterparts. The aim of this study was to assess the presence of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) in comparison with patients with rheumatoid arthritis (RA) and healthy controls. Methods: A total of 30 patients with PsA, 30 patients with RA, and 30 healthy controls were enrolled in this parallel group study. Demographic, clinical, and laboratory data of the groups were recorded. The Disease Activity Score-28 tool was used for joint assessment. The erythrocyte sedimentation rate and C-reactive protein level were measured as acute phase reactants. Flow-mediated dilatation (FMD) and carotid intima media thickness (CIMT) were also measured in all participants. Results: The median duration of disease in patients with PsA was 60 months (range: 8–216 months). A total of 22 of 30 (73.3%) PsA patients had a diagnosis of psoriasis and 13 (48.1%) had active disease. The study groups were similar with regard to age, gender, and body mass index data. In all, 23 (76.7%) of the PsA patients and 5 (16.7%) of the RA patients were using an anti-tumor necrosis factor alpha therapy (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|